Enovis (ENOV) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Company Overview and Strategic Direction

• MedTech company with over $2 billion in revenue, balanced between high-growth Recon and Prevention & Recovery (P&R) segments, and a strong global presence.

• Strategy centers on organic and acquisition-driven growth in Recon, operational excellence, continuous innovation, and portfolio shaping for higher margins and cash flow.

• EGX Enovis Growth Excellence Business System underpins continuous improvement and lean operations, supporting transformation from a diversified industrial to a focused MedTech company.

• International sales mix increased from 27% in 2019 to over 40% in 2024e, driven by focused M&A and global channel expansion.

• Over 20 acquisitions since 2019, including Lima and Mathys, have accelerated revenue growth, margin profile, and global reach.

Recent Performance and Integration

• Lima acquisition led to a step change in revenue and EBITDA margins, with successful first-year integration and achievement of financial and strategic goals.

• Integration impacts temporarily pressured organic growth, but the company is now positioned for higher organic growth and further cost and cross-selling synergies over the next three years.

• Integration of Lima is ahead of plan, with over $10M cost synergies in year 1 and a path to over $40M over three years.

• Disruption from integration, especially in the U.S., peaked in Q2 2023 and is now largely resolved, with no major integration impacts expected in 2025.

• Outside the U.S., integration was completed quickly, with final adjustments in Q4 and Q1.

Growth Drivers and Innovation

• Recon business (~$1B) is focused on high-growth extremities (shoulder, foot, ankle) and maintains strong positions in hip and knee, supported by differentiated technologies and a robust channel.

• Consistent above-market growth in Recon, with high single-digit to low double-digit growth targeted, leveraging cross-selling and innovation pipeline.

• Enabling technologies such as ARVIS (augmented reality navigation), AI-driven planning, and Match Point Planning System drive workflow improvements and competitive differentiation.

• Over 30 new product launches planned in the next three years, including global rollout of ARVIS and new solutions in shoulder and hip.

• P&R segment is #1 globally in bracing and #2 in bone stimulation, with strong international presence and digital workflow leadership.